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Abstract
Substituted pyrazole esters were identified as hits in a high throughput screen (HTS) of the NIH Molecular
Libraries Small Molecule Repository (MLSMR) to identify inhibitors of the enzyme cathepsin B. Members of
this class, along with functional group analogs, were synthesized in an effort to define the structural
requirements for activity. Analog characterization was hampered by the need to include a reducing agent such
as dithiothreitol (DTT) or cysteine in the assay, highlighting the caution required in interpreting biological
data gathered in the presence of such nucleophiles. Despite the confounding effects of DTT and cysteine, our
studies demonstrate that the pyrazole 1 acts as alternate substrate for cathepsin B, rather than as an inhibitor.
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Abstract—Substituted pyrazole esters were identiﬁed as hits in a high throughput screen (HTS) of the NIH Molecular Libraries
Small Molecule Repository (MLSMR) to identify inhibitors of the enzyme cathepsin B. Members of this class, along with functional
group analogs, were synthesized in an eﬀort to deﬁne the structural requirements for activity. Analog characterization was hampered
20 by the need to include a reducing agent such as dithiothreitol (DTT) or cysteine in the assay, highlighting the caution required in
interpreting biological data gathered in the presence of such nucleophiles. Despite the confounding eﬀects of DTT and cysteine, our
studies demonstrate that the pyrazole 1 acts as alternate substrate for cathepsin B, rather than as an inhibitor.
 2007 Elsevier Ltd. All rights reserved.
Cathepsins play an important role in cellular protein
degradation through the lysosomal pathway,1 and as
such, represent a signiﬁcant class of drug targets, having
been implicated in a variety of degenerative and invasive
30 processes including: asthma, Alzheimer’s disease,2 can-
cer,3,4 diabetes, inﬂammatory diseases,5 liver disorders,
multiple sclerosis, muscular dystrophy, and pancreati-
tis.6 The large number of disease states associated with
the biological eﬀects of the cathepsin protease family,
and speciﬁcally cathepsin B, demands an understanding
of their biological function. The availability of small
molecule probes of the cathepsins thus holds the prom-
ise both for characterization of this ubiquitous enzyme
class and for the discovery of new cysteine protease
40 inhibitors of considerable biomedical value.3,7,8
Recently, the Penn Center for Molecular Discovery
(PCMD)9 completed a high throughput screen
(HTS) to identify small molecule probes (i.e., inhibi-
tors) for the papain-like cysteine protease family,
including cathepsins B, L, and S. While a number
of both potent and selective inhibitors have been de-
scribed previously,2–8 this project presented an oppor-
tunity to annotate the NIH Molecular Libraries
Small Molecule Repository (MLSMR) through depo-
50sition of data in PubChem.10 As such, this work rep-
resents one of the ﬁrst eﬀorts to create a
comprehensive, publicly available proﬁle of small-
molecule inhibitors of the cysteine protease class.
Screening 63,332 members of the MLSMR against
human liver cathepsin B resulted in a number of
hits.11 Further conﬁrmatory assays included IC50
determination and elimination of false positives
resulting from non-speciﬁc redox chemistry.12 Based
on these results, a family of substituted pyrazole
60esters was identiﬁed that displayed promising activity
as inhibitors of cathepsin B (Table 1).13
0960-894X/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
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The pyrazole series (1–6) displayed suitable physico-
chemical properties (MW 347–379 and XlogP = 2.7–
3.3) with structurally related analogs revealing a range
of activities in our HTS analysis. Based on these attri-
butes, members of this series were viewed as potential
small molecule lead compounds for the inhibition of
cathepsin B, and as such were selected for further study
to understand and improve their biological proﬁle.
70 Structurally related pyrazoles that were inactive in the
HTS assay were compared to compounds 1–6 in a pre-
liminary eﬀort to understand the requirements for activ-
ity. Based on this analysis, we pinpointed the ester group
as a functional moiety important for activity; we rea-
soned that the ester could act as an electrophilic site that
would react with the active site cysteine. Alternatively,
the compound could behave as an alternate substrate
of the enzyme resulting in transesteriﬁcation or hydroly-
sis of the ester functionality. To diﬀerentiate these two
80 scenarios, a series of analogs were constructed and sub-
jected to biochemical and analytical studies to deﬁne the
mechanism of action. Herein we report the results of this
eﬀort.
To conﬁrm both the activity and identity of the original
hits, we resynthesized compounds 1–6.14,15 This exercise
permitted both the development of an eﬀective method
to construct the pyrazole scaﬀold and the preparation
of analogs. The synthesis of 1,3-disubstituted-5-amino-
pyrazoles (1–6) began with commercially available cya-
90noacetohydrazide (7) and the appropriate aryl-
substituted sulfonyl chlorides, according to the proce-
dure of Elgemeie et al.16,17 Reaction of 7 with the aryl-
substituted sulfonyl chlorides in ethanol furnished the
sulfonamides 8–11 which conveniently precipitated from
solution (Scheme 1).
As expected, the major by-products, aryl ethyl sulfo-
nates, remained soluble and were easily removed from
8–11 via ﬁltration. Thus, on a 50 mmol scale, gram
quantities of the required sulfonamide hydrazides could
100be readily prepared in high purity. Eﬃcient cyclizations
of sulfonamide hydrazides (8–11) to pyrazolones (12–15)
occurred upon treatment with an aqueous solution of
NaOH, followed by acidiﬁcation (10% HCl) to precipi-
tate the pyrazolones.18 The pyrazolones were used in
the subsequent acylation step without puriﬁcation. For
example, treatment of 12–15 with 2-thiophenecarbonyl
chloride or 2-furancarbonyl chloride in chloroform re-
sulted in chemoselective19 acylation at the C3-oxygen
versus the C5-amino group to furnish pyrazoles 1–6 in
110moderate to good yields after silica gel chromatography.
The availability of newly synthesized pyrazoles 1–6 al-
lowed conﬁrmation of the structures and observed bio-
logical activity of the initial hits. Pleasingly, both the
structures and re-assay IC50 values of synthetic pyraz-
oles 1–6 were in agreement with the results obtained
from the original screening experiments (Table 1).
The ester carbonyl carbon in 1, activated by the adjacent
pyrazole, is a likely site for nucleophilic attack by the ac-
tive site cysteine-25 sulfur in cathepsin B. In order to as-
120sess the electrophilicity of this carbon atom, equilibrium
geometries and electrostatic potential surfaces were cal-
culated for 1 using PC Spartan software.20 The known
cysteine protease inhibitor E6421 was also analyzed for
comparison to pyrazole ester 1 (Fig. 1).
As expected, the most electrophilic center for pyrazole
ester 1 was the carbonyl carbon of the ester, with an
electrostatic potential value of 128.0 kJ/mol. The carbons
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Scheme 1. Synthetic procedure to prepare pyrazole esters 1–6.
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Figure 1. Compounds for which electrostatic potential surfaces were
calculated: pyrazole ester 1 and E64.
Table 1. Pyrazole HTS hits in the cathepsin B assay
N
NH2N
O
O
S
O
O
R
X
1- 6
PubChem SID X R IC50
a (lM)
4249135 (1) S H 0.25 ± 0.03
4247730 (2) S F 0.44 ± 0.11
4245669 (3) S OMe 0.69 ± 0.10
844213 (4) S Me 1.99 ± 0.17
849441 (5) O Me 1.75 ± 0.06
845259 (6) O F 1.26 ± 0.04
a IC50 values are reported as means ± standard deviation (number of
determinations = 3).
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of the epoxide ring in E64 had values of 104.3 and 104.7
for their electrostatic potential surface energies. The
130 greater positive value of 128.0 kJ/mol suggests that the
carbonyl carbon of 1 is more prone to nucleophilic attack
than the epoxide carbons in the irreversible cathepsin B
inhibitor E64. This diﬀerence in electrophilicity was
conﬁrmed experimentally (vide infra). Presumably, the
stability of the pyrazolone by-product of 1 provides the
driving force for attack of this atom center.
We reasoned that, modulating the electronic parameters
of the electrophilic ester functionality in this series of
compounds would quickly validate or eliminate the
140 importance of this structural feature. To test this
hypothesis, pyrazole 14 was employed as a common
intermediate to construct ether 16, sulfonate 17, and
isonicotinoyl ester 18 (Fig. 2).
Ether 16 was formed via an alkylation of 14 with 2-bro-
momethyl-thiophene22 in moderate yield. Sulfonate 17
and isonicotinoyl ester 18 were constructed under
chemoselective acylation conditions similar to those em-
ployed to prepare pyrazoles 1–6.19 In support of the
requirement of the ester functionality for biological
150 activity, ether 16 and sulfonate 17 were found to be inac-
tive. Surprisingly, however, related ester analog pyridine
18 was devoid of activity, despite its steric and electronic
similarity to the thiophene moiety found in 1. This unex-
pected result led us to question the stability of the pyra-
zole hits (e.g., hydrolysis or transesteriﬁcation) under
the assay conditions. To probe these issues, we under-
took further biological characterization of 1, as well as
a detailed analysis of assay by-products. Kinetic analysis
of the inhibition of cathepsin B by 1 revealed a compet-
160 itive inhibition pattern, in which 1 increased the Km of
the substrate but had no eﬀect on the Vmax. The Ki of
1 was determined to be 0.9 lM (±) 0.25 lM (Fig. 3).23
Reversibility of inhibition was next demonstrated by
incubating cathepsin B with 1 at a concentration that
gave complete inhibition followed by determination of
enzyme activity after 100-fold dilution. As expected for
reversible inhibition, the enzyme regained full activity
upon dilution.24
These experiments ruled out the possibility that 1 acts
170 similar to E64, an irreversible inhibitor. The possibility
that 1 acted as a substrate of cathepsin B, however, re-
mained. That is, under the conditions employed for
the kinetic analyses, a competitive inhibitor is indistin-
guishable from an alternate substrate.23 Thus, experi-
ments were carried out to evaluate the reactivity of 1
under the assay conditions.
As a control, a biochemical time course experiment was
designed. Pyrazole 1 was combined with the assay buﬀer
(phosphate, pH 6.8) over a series of time points (0, 2, 17,
180and 24 h). Samples at each time point were then incu-
bated with cathepsin B (0.1 nM) in the buﬀer
(100 mM) containing dithiothreitol (DTT) (2 mM) un-
der the standard assay conditions, and IC50 data were
measured.13 Results from these experiments indicated
a signiﬁcant loss of inhibitory activity which correlated
with the time of pre-incubation (Table 2).
The IC50 values of pyrazole 1 increased from 1.42 lM at
a pre-incubation time of 0 h to >50 lM at an incubation
time of 24 h. Two additional experiments were con-
190ducted to pinpoint the cause of the time dependent loss
of activity: (1) pyrazole 1 was added to an assay buﬀer
that did not contain DTT (Column 2, Table 2); and
(2) pyrazole 1 was added to a non-buﬀered solution also
without DTT (Column 3, Table 2). Both experiments re-
vealed that the IC50 values changed slightly from the 0
N
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N
NH2N
O
S
O
O
OMe
R
S
R
SS
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Figure 2. Reagents and conditions: (a) 2-bromomethyl-thiophene,
K2CO3, DMF, 0–23 C, 3 h, 50%; (b) thiophene-2-sulfonyl chloride,
Et3N, CHCl3, 23 C, 2 h, 76%; (c) isonicotinoyl chloride, Et3N, CHCl3,
23 C, 2 h, 43%.
Figure 3. Kinetic characterization of inhibition of cathepsin B by 1.
Cathepsin B was assayed with combinations of 20–350 lMZ-Arg-Arg-
AMC substrate and 0.17–1.3 lM inhibitor (1). Initial rates of product
release were determined by measuring increase in ﬂuorescence over
15 min. Data were ﬁt by non-linear regression using IDBS XLﬁt. (a)
Rate of enzyme-catalyzed substrate hydrolysis as a function of its
concentration. Substrate concentration was varied from 20 to 350 lM
in the presence of 0 lM (), 0.17 lM (h), 0.25 lM (n), 0.39 lM (j),
0.58 lM (m), 0.87 lM (s), and 1.3 lM () compound 1. (b) Replot of
Km values calculated by non-linear ﬁt of curves in (a). Linear
regression gave a Ki value of 0.9 lM with a standard error of 0.25 lM.
Table 2. Time dependent pre-incubation of 1 with and without DTT:
an analysis of 1 in the cathepsin B assay
Pre-incubation
time (h)
IC50
a (lM)
Assay buﬀer
with DTT
Assay buﬀer
without DTT
Non-buﬀered
without DTT
0 1.4 0.8 0.8
2 9.0 1.4 1.7
17 45.4 0.7 1.8
24 >50 3.2 5.0
a IC50 values are calculated from a dose response curve of 16 2-fold
dilutions.
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to 24 h incubation time. Thus, the presence of DTT was
deemed largely responsible for the signiﬁcant loss in
activity.
With these results in hand, we set out to deﬁne more pre-
200 cisely the role of DTT in the inactivation of 1. Analytical
experiments were designed to mimic the biological pre-
incubation experiment, wherein the aqueous solutions
of 1 with and without DTT would be analyzed via
LC–MS for hydrolysis products (e.g., pyrazolone 12).
The LC–MS analysis corroborated the previous
study and also provided an additional detail, the loss
of 1 was the result of its conversion to pyrazolone 12
(Table 3).
For example, when 1 was incubated in the DTT contain-
210 ing assay buﬀer, conversion to 12 occurred quickly with
28% of 1 remaining after 1 h, and only 12% after 24 h.25
Hydrolysis of 1 to 12 also occurred, albeit slowly, in
both buﬀer without DTT and non-buﬀered water. How-
ever, on the time-scale of the HTS assay, the contribu-
tion of this degradation pathway to the activity was
negligible. Additional experiments indicated that when
E64 was exposed to DTT (under the same conditions
as listed in Table 3.) it was found to be stable with no
E64 decomposition and no DTT-E64 adduct formed,
220 as monitored by LC–MS.
Anticipating that 12 could arise via nucleophilic dis-
placement of the thiophene ester with DTT, we
examined the LC–MS data for the anticipated transeste-
riﬁed DTT-thiophene ester product 19 (Scheme 2).
The molecular ion corresponding to 19 (M+1 = 265)
was observed in the LC–MS analysis of the assay buﬀer
with DTT. As further veriﬁcation, adduct 19 was syn-
thesized independently using DTT and 2-thiophenecar-
bonyl chloride, and used as a standard in the LC–MS
230analysis. Bioassay of 19 with cathepsin B revealed no
activity. Taken together, these data reveal the basis for
the diminished IC50 values following extended pre-incu-
bation times.
The inherent redox chemistry associated with DTT is
well known, both in connection with the identiﬁcation
of false positives in cysteine protease assays and with en-
zymes such as phosphatases.12,26–28 To avoid the redox
issues of DTT, cysteine is often used in place of DTT
due to its lower oxidation potential. Less well appreci-
240ated, however, is the propensity of DTT to act as a
nucleophile, thereby confounding bioassay results.29,30
Unfortunately, in our case, replacement of DTT with
cysteine does not alleviate the problem. Indeed, the same
fast conversion of 1–12 was observed, via LC–MS, in the
presence of cysteine. Thus, the series of pyrazole esters is
susceptible to both the hydrolysis and transesteriﬁcation
pathways. We were, however, intrigued by the apparent
lack of any activity of 18, despite the similar size and
electronic attributes of the ester moiety. To explore this
250observation, we analyzed the rate of hydrolysis and
transesteriﬁcation of 18. Surprisingly, incubation of 18
in assay buﬀer, with and without DTT, and a non-buf-
fered aqueous solution, revealed rapid conversion (ca.
1 h) to pyrazolone 14, regardless of the presence of
DTT (Table 4).25
The ease of hydrolysis and esteriﬁcation of 18 is likely a
reﬂection of the fact that the pyridine ring is partially
protonated under the conditions.31 Thus, within the
timescale of the cathepsin B assay (1 h incubation with
260the enzyme), a negligible amount 18 would be present.
Taken together, the results support the hypothesis that 1
acts as an alternate cathepsin B substrate rather than an
Table 3. Time dependent pre-incubation of 1 with and without DTT:
an analysis of 1 by LC–MSa
N
NHH2N
S
O
O
O
12
conditions
N
NH2N
O
O
S
O
O
S
1
+     1
Incubation
time (h)
% conversion of 1–12
Assay buﬀer
with DTT
Assay buﬀer
without DTT
Non-buﬀered
without DTT
1 72 5 5
2 80 5 6
16 87 13 11
24 88 17 9
a LC–MS analysis conducted on a 6.5 min run time (100 lM sample
concentration).
S
O
SHS
OH
OH
SH
HS
OH
OH
DTT = 
DL-1,4-dithiothreitol
thiophene-2-carbonyl
chloride, Et3N, CHCl3
HPLC purification
19
Scheme 2. Synthesis of DTT-thiophene adduct 19.
Table 4. Time dependent pre-incubation of 18 with and without DTT:
an analysis of 18 by LC–MSa
N
NHH2N
S
O
O
O
14
conditions
N
NH2N
O
O
S
O
O
18
N
OMe
OMe
+  18
Incubation
time (h)
% conversion of 18–14
Assay buﬀer
with DTT
Assay buﬀer
without DTT
Non-buﬀered
without DTT
1 >99 41 15
2 >99 80 24
16 >99 >99 95
24 >99 >99 99
a LC–MS analysis conducted on a 6.5 min run time (100 lM sample
concentration).
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like DTT to transesterify 1, and thereby forms a tran-
sient thiophenoyl-enzyme intermediate.7,32,33 To test this
scenario, a stoichiometric reaction was devised to incu-
bate pyrazole ester 1 (1 equiv) with and without cathep-
sin B (2 equiv) (Table 5).
Under these stoichiometric reaction conditions, in the
270 presence of cathepsin B, pyrazole 1 was fully converted
to 12 after only 15 min. However, under identical condi-
tions, in the absence of cathepsin B, 50% of pyrazole 1
remained.34 We conclude that pyrazole esters such as 1
are competitive substrates for the enzyme cathepsin B.
In summary, we have demonstrated that pyrazole 1 acts
as an alternate substrate for the cysteine protease,
cathepsin B. Synthesis and evaluation of related analogs
revealed the potential reactivity of the ester functionality
with the nucleophilic enzyme active site cysteine to form
280 a transient thiphenoyl-enzyme intermediate. Initially,
the similar reactivity of DTT and cysteine, in the bioas-
say, confounded the HTS and subsequent assay results
due to the nucleophilic properties of the thiol sulfur.
Thus, it is important for the biological and chemical
communities to consider the potential of DTT and cys-
teine to act as nucleophiles in assay systems where sub-
strates contain electrophilic functionality.
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